[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fj1lUvPUMh4Vv0ilOVdIiV238A-6T503thaSbNbb7tt8":8,"$fqBkw45HOgRGVSZMFraBBZfCexbPHC2Ua4gd9n8XqrOs":54,"$fuqhx4r38LoWGe7q28HnyELr2MYvIf_ohnROmLguvoW0":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":20,"quality":52,"commentCount":21,"isComment":20},67377,870811,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//pwDqbHq74RDuAAIRhpa4DFXgjJHyAxSu.png","钟献","浙江大学医学院附属第二医院","肿瘤科","副主任医师",1,0,"膀胱癌术后复发治疗：科学应对与用药指南 💊","","https://cdn.yishi-tong.com/console/store-26/bxe5hFjP79_92hj3YtY3J-E2mpObOUD0.png","\u003Cdiv id=\"material_title\" class=\"bladder-drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">膀胱癌术后复发治疗：科学应对与用药指南 💊\u003C/h2>\n\u003C/div>\n\n\u003Cdiv class=\"bladder-drug-intro\">\n  \u003Cp>\n    有不少患者在膀胱手术后会选择化疗或免疫药物辅助治疗，这些药物有着各自独特的使用方法和注意事项。说起来，用药细节往往决定了疗效与安全，正确操作才能降低风险。本文将分七大部分，详细解读膀胱癌术后复发相关药品（如吉西他滨、紫杉醇、PD-1抑制剂）从成分、机制到用法、安全和常见相互作用的问题，帮你一次掌握关键用药流程。\n  \u003C/p>\n\u003C/div>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-1\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药物种类与主要成分 👨‍🔬\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        吉西他滨（Gemcitabine）：核苷类似物，常见静脉注射剂型。\n      \u003C/li>\n      \u003Cli>\n        紫杉醇（Paclitaxel）：微管抑制剂，以注射液形式使用。\n      \u003C/li>\n      \u003Cli>\n        PD-1抑制剂（如卡瑞利珠单抗/Camrelizumab）：单克隆抗体类，免疫调节作用，注射剂。\n      \u003C/li>\n      \u003Cli>\n        辅助药品配合：部分患者还会联合使用抗恶心止吐药、粒细胞刺激因子作配套预防，需区别对待。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">正确做法：\u003C/span>了解所用药品具体名称与成分，避免混用同类药物或不清楚药品来源。不同药品虽然都用于复发后的治疗，但组成和目标完全不同，使用前务必查明具体成分。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-2\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 作用机制简述 🧬\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>吉西他滨：\u003C/strong>干扰细胞DNA合成，阻止癌细胞分裂。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>紫杉醇：\u003C/strong>抑制细胞微管形成，使癌细胞无法顺利有丝分裂。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong>解除肿瘤对免疫系统“隐身”作用，激活T细胞清除异常细胞。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">需要注意：\u003C/span>这三类药品作用机制差异大，选择方案时通常由专业医生根据病例情况决定，单独使用和联合用药目的不同。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-3\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药时间与具体方法 ⏰\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        吉西他滨：静脉注射给药，多为每周一次或按疗程分段进行，每剂需缓慢滴注，时间要在30分钟至60分钟之间。\n      \u003C/li>\n      \u003Cli>\n        紫杉醇：点滴静注，每1-3周给药一次，具体周期由医生设定。滴注时需用非PVC输液器以防与药液发生反应。\n      \u003C/li>\n      \u003Cli>\n        PD-1抑制剂：一般为每2-3周注射一次，剂量和周期需精准掌控，遵循说明书要求，由专科医师监督。\n      \u003C/li>\n      \u003Cli>\n        辅助药用法：化疗常搭配预防恶心药（如昂丹司琼），需提前30分钟口服或静脉注射，加强防护。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">正确做法：\u003C/span>严格遵守剂量、频次和输液时长；不可自行更改周期，不可自行混合药液或中断疗程。如遇漏服或推迟，仅可在医生指导下调整。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-tip\">临床用药案例：\u003C/span>一位59岁男性膀胱癌患者在术后，采用了吉西他滨联合紫杉醇及PD-1抑制剂，按规定周期点滴，过程由护士全程监护，有效降低药物毒性。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-4\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 剂型选择与服用技巧 💡\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        所有药品首选静脉输注，无口服、肠溶或缓释制剂。不得自行改成其他给药途径。\n      \u003C/li>\n      \u003Cli>\n        配药时应由专业药师在无菌条件下操作，每种药品均有专用溶剂和稀释要求。\n      \u003C/li>\n      \u003Cli>\n        滴注过程中切勿私自加药，输液完成后及时拔针，局部按压防止渗漏。\n      \u003C/li>\n      \u003Cli>\n        滴注药品过程中如遇堵塞、药液变色，应立即报告医护，严禁摇晃或重新加热药液。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">正确做法：\u003C/span>每次给药由专业人员操作，按剂型规定完成整个过程。家属不得自行处理或更换药液。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-5\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用与用药禁忌 ⚠️\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        吉西他滨与紫杉醇联合增效，但如同时使用其他抗癌药（如多柔比星），可能加重骨髓抑制作用，应避开重叠用药。\n      \u003C/li>\n      \u003Cli>\n        PD-1抑制剂使用期间禁止合用免疫抑制药如糖皮质激素（非特殊情况），否则免疫激活效果会被削弱。\n      \u003C/li>\n      \u003Cli>\n        化疗期间应避免联用有肝肾毒性的药物，防止药品代谢负担过重，如某些抗生素及中草药（详见说明书）。\n      \u003C/li>\n      \u003Cli>\n        有特定药品相互作用需提前“间隔”服用。例如：PD-1抑制剂与抗病毒药需相隔48小时，不宜同天使用。\n      \u003C/li>\n      \u003Cli>\n        禁忌人群包括严重肝肾功能不全者、对所用药品过敏者、怀孕及哺乳期女性（说明书列明）。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">特别提醒：\u003C/span>每次配药前务必报备所有正在使用药品和保健品清单，如有不明成分及时停用。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-tip\">案例参考：\u003C/span>临床曾有患者同时服用多种抗肿瘤药导致严重白细胞减少，后经调整药物时间及种类，恢复正常。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-data\">数据表明：\u003C/span>联合化疗方案骨髓抑制概率上升至55%（REF: Petrylak et al., 2017），联合免疫治疗出现免疫相关不良反应约18%（REF: Alva et al., 2019）。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-6\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及处理办法 🚑\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>吉西他滨：\u003C/strong>容易出现发热、粒细胞减少、肝酶升高等反应。应定期化验血常规，及时发现异常。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>紫杉醇：\u003C/strong>常引起周围神经病变、脱发、手脚麻木，如用药2周内明显加重需尽快停药评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>PD-1抑制剂：\u003C/strong>有时出现皮疹、乏力及免疫相关炎症，少数情况可致内分泌紊乱。应出现反常皮肤或体力变差时立刻就医。\n      \u003C/li>\n      \u003Cli>\n        恶心、呕吐多以预防性服药控制，用药后4小时仍持续需复查。\n      \u003C/li>\n      \u003Cli>\n        过敏反应（面色潮红、呼吸急促等）需急停药液，并立即告知医生，进行急救处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">正确做法：\u003C/span>每次用药后3天内注意不良反应变化，出现异常第一时间报警不自行处置。用药间隔期需加强体检。\n    \u003C/p>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-tip\">临床经验：\u003C/span>一位患者化疗期间出现白细胞跌至最低点，医护及时注射粒细胞生成素，成功避免感染并发症。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-7\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 药品储存方法与有效期 ⏳\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        吉西他滨、紫杉醇及PD-1抑制剂原药需冷藏2-8°C，绝不可冷冻或曝晒阳光。\n      \u003C/li>\n      \u003Cli>\n        配好的药液当天应使用，剩余药液不得留作下次用药。\n      \u003C/li>\n      \u003Cli>\n        药品存放需避光、防潮、远离儿童和宠物，开封药品如药液变色变味，务必丢弃不得继续用。\n      \u003C/li>\n      \u003Cli>\n        药品过期后不得“凑用”，需交由医院或正规回收渠道处理，严禁自行倾倒入下水道或垃圾桶。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">需要注意：\u003C/span>日常储存时必须定期检查药品有效期和包装完整性，家中常备药品注意分区存放。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-8\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服与过量处理 🛑\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>漏服：\u003C/strong>如某次化疗因故未按时完成，应由医师制定补充计划；绝不可自行增加剂量或缩短下次间隔。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量：\u003C/strong>化疗或免疫药品超剂量容易引起严重骨髓抑制、肝肾衰竭及过敏反应，一旦发生必须立刻送医处理，不可拖延或自行服用其它药物缓解。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>安全警示：\u003C/strong>绝不随意调整用药计划或补药，应全程让医护团队知情并协助处置用药风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">正确做法：\u003C/span>如不慎漏服或多服，不要自行补偿，及时与专科医生沟通，按建议调整下一疗程时间。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-9\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 特殊人群用药注意事项 🧓🧑‍🦳\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cul>\n      \u003Cli>\n        老年患者常因肝肾功能下降，需要酌情降低剂量或延长间隔。\n      \u003C/li>\n      \u003Cli>\n        儿童和青少年极少应用此类方案，必须在权威中心严格监护。\n      \u003C/li>\n      \u003Cli>\n        妊娠及哺乳期患者全部禁用，避免胎儿或婴儿毒副影响。\n      \u003C/li>\n      \u003Cli>\n        已知有药品过敏史者禁用，必须提前试验性皮试。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      \u003Cspan class=\"bladder-drug-note\">特别提醒：\u003C/span>所有人群均不得随意增减剂量或改变用药方式，特殊情况需制定个体化方案。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-10\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 总结与注意事项回顾 📝\u003C/h2>\n  \u003Cdiv class=\"bladder-drug-content\">\n    \u003Cp>\n      在膀胱癌术后复发药物治疗中，坚持规范用药才是保证疗效和安全的关键。每一次给药均需专业人员监护，剂量、时间、配药和储存细节都不可随意，把握不良反应和相互作用风险，才有可能获得良好治疗结局。\u003Cbr>\n      最重要的两点：\u003Cstrong>一是不可自行调整方案\u003C/strong>，二是必须全程报备所有药品信息。遇到不良反应或药品异常，及时反馈医生，不拖延不自行处理。日常储存和护理环节也需高度重视。\u003Cbr>\n      药品本身只是治疗的一环，合理管理才能最大限度发挥作用。建议把这些注意事项整理记录家中，方便家属和本人随时查验。如需详细方案调整，一定咨询肿瘤科或药学专家。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"bladder-drug-section bladder-bg-ref\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 📚\u003C/h2>\n  \u003Cul class=\"bladder-drug-ref-list\">\n    \u003Cli>\n      Petrylak, D.P., Tangen, C.M., et al. (2017). \"Gemcitabine and paclitaxel versus gemcitabine and carboplatin as first-line chemotherapy for advanced urothelial carcinoma.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 35(6), 421–429.\n    \u003C/li>\n    \u003Cli>\n      Alva, A.S., Mangat, P.K., et al. (2019). \"Pembrolizumab in patients with advanced urothelial carcinoma: safety and efficacy by prior chemotherapy.\" \u003Cem>Journal of Clinical Oncology\u003C/em>, 37(29), 2618–2626.\n    \u003C/li>\n    \u003Cli>\n      Bellmunt, J., de Wit, R., et al. (2017). \"Immune checkpoint inhibitors in urothelial carcinoma: Update on clinical outcomes.\" \u003Cem>European Urology\u003C/em>, 71(2), 240–253.\n    \u003C/li>\n    \u003Cli>\n      National Comprehensive Cancer Network (NCCN). (2023). \u003Cem>NCCN Guidelines: Bladder Cancer\u003C/em>. Version 1.2023.\n    \u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Cstyle>\n.bladder-drug-title {\n  background: linear-gradient(90deg, #cbe7fa 0%, #eaf2fb 100%);\n  padding: 42px 0 26px 0;\n  text-align: center;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n  color: #2573b6;\n  border-radius: 6px;\n  margin-bottom: 28px;\n}\n\n.bladder-drug-intro {\n  background: linear-gradient(90deg, #f7f7fa 0%, #e2f4ff 100%);\n  font-size: 21px;\n  color: #363946;\n  border-radius: 6px;\n  padding: 32px 28px 20px 28px;\n  margin-bottom: 32px;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n}\n\n.bladder-drug-section {\n  margin-bottom: 35px;\n  border-radius: 8px;\n  box-shadow: 0 2px 10px 0 #ccdcf2;\n  max-width: 900px;\n  margin-left: auto;\n  margin-right: auto;\n  padding: 0;\n}\n.bladder-drug-section h2 {\n  font-size: 28px;\n  font-weight: bold;\n  letter-spacing: 1px;\n  padding: 52px 34px 32px 38px;\n  border-radius: 8px 8px 0 0;\n  margin-bottom: 0;\n  color: #3177bf;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n}\n.bladder-drug-content {\n  font-size: 21px;\n  color: #30394b;\n  line-height: 1.7;\n  padding: 22px 38px 34px 38px;\n  background: #f9fcff;\n  border-radius: 0 0 8px 8px;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n}\n.bladder-drug-content ul {\n  margin-left: 1.2em;\n  margin-bottom: 20px;\n}\n.bladder-drug-content li {\n  margin-bottom: 12px;\n}\n\n.bladder-drug-note {\n  background: #eaedff;\n  color: #2353ad;\n  font-weight: bold;\n  padding: 2px 10px 2px 10px;\n  border-radius: 4px;\n  margin-right: 8px;\n}\n\n.bladder-drug-tip {\n  background: #e6f3fc;\n  color: #288f60;\n  font-weight: 500;\n  padding: 2px 10px 2px 10px;\n  border-radius: 4px;\n  margin-right: 8px;\n}\n\n.bladder-drug-data {\n  background: #fbeccd;\n  color: #af6d00;\n  font-weight: 500;\n  padding: 2px 8px 2px 8px;\n  border-radius: 4px;\n  margin-right: 8px;\n}\n\n.bladder-bg-1 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2NkZGVmZiIgLz48L3N2Zz4=\") repeat-x top center;\n}\n.bladder-bg-2 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2VmZmVkZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-3 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjExMCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMTAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMTAiIHJ4PSIxNCIgZmlsbD0iI2VmZmJmZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-4 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2VhZGNmZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-5 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2VmZWZjNSIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-6 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjExMCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMTAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMTAiIHJ4PSIxNCIgZmlsbD0iI2Y4ZWVjZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-7 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEyMCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMjAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMjAiIHJ4PSIxNCIgZmlsbD0iI2VmZmVmZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-8 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2Y5ZWVlZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-9 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEwOCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMDgiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMDgiIHJ4PSIxNCIgZmlsbD0iI2VmZWNkZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-10 {\n  background: url(\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iOTAwIiBoZWlnaHQ9IjEyMCIgZmlsbD0ibm9uZSIgdmlld0JveD0iMCAwIDkwMCAxMjAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyI+PHJlY3Qgd2lkdGg9IjkwMCIgaGVpZ2h0PSIxMjAiIHJ4PSIxNCIgZmlsbD0iI2QwZEVmZiIvPjwvc3ZnPg==\") repeat-x top center;\n}\n.bladder-bg-ref {\n  background: linear-gradient(90deg, #f7f9fa 0%, #e2e6ee 100%);\n  border-radius: 8px;\n  box-shadow: none;\n  margin-bottom: 46px;\n  max-width: 880px;\n  margin-left: auto;\n  margin-right: auto;\n  padding: 0px;\n}\n.bladder-bg-ref h2 {\n  font-size: 27px;\n  color: #626684;\n  padding: 42px 34px 8px 38px;\n  border-radius: 8px 8px 0 0;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n}\n.bladder-drug-ref-list {\n  font-size: 19px;\n  color: #405073;\n  background: #f0f4fa;\n  border-radius: 0 0 8px 8px;\n  padding: 20px 44px 30px 52px;\n  font-family: 'Segoe UI', 'Microsoft YaHei', sans-serif;\n  line-height: 1.55;\n  list-style-type: disc;\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"bladder-drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.",563,"2025-09-28 14:50:40","膀胱癌, 化疗, 免疫药物, 用药指南, 复发治疗","本文详细解析膀胱癌术后复发的药物治疗，包括用药机制、注意事项和不良反应，帮助患者和家属更科学地管理治疗方案。","2025-10-03 06:03:22",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":20,"status":21,"createDept":6,"remark":23,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":20,"isHome":21,"forceLogin":21,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T","2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":20,"pageSize":56,"result":57,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]